REGN Regeneron Pharmaceuticals Inc

USD 1,039.11 0.00 0
Icon

Regeneron Pharmaceuticals Inc (REGN) Stock Analysis and Price Targets

COMMON STOCK | Biotechnology | NSD
stockTargetAdvisor

Buy

Average Analyst
Rating
stockTargetAdvisor

Buy

Top Analyst
Rating
stockTargetAdvisor

Bullish

Stock Target Advisor
Analysis
stockTargetAdvisor

Strong Buy

Average User
Rating

USD 1,039.11

0.00 (0.00)%

USD 115.08B

0.38M

N/A

USD 755.40 (-27.30%)

Icon

REGN

Regeneron Pharmaceuticals Inc (USD)
COMMON STOCK | NSD
USD 1,039.11
0.00 0
Take a Tour
stockTargetAdvisor

Buy

Average Analyst
Rating
stockTargetAdvisor

Buy

Top Analyst
Rating
stockTargetAdvisor

Bullish

Stock Target Advisor
Analysis
stockTargetAdvisor

Strong Buy

Average User
Rating

USD 115.08B

USD 755.40 (-27.30%)

USD 1,039.11

Regeneron Pharmaceuticals Inc (REGN) Stock Forecast

Show ratings and price targets of :
USD 1,017.13
(-2.12%)

Based on the Regeneron Pharmaceuticals Inc stock forecast from 11 analysts, the average analyst target price for Regeneron Pharmaceuticals Inc is USD 1,017.13 over the next 12 months. Regeneron Pharmaceuticals Inc’s average analyst rating is Buy . Stock Target Advisor’s own stock analysis of Regeneron Pharmaceuticals Inc is Bullish , which is based on 10 positive signals and 4 negative signals. At the last closing, Regeneron Pharmaceuticals Inc’s stock price was USD 1,039.11. Regeneron Pharmaceuticals Inc’s stock price has changed by +1.11% over the past week, +5.78% over the past month and +32.70% over the last year.

No recent analyst target price found for Regeneron Pharmaceuticals Inc
No recent average analyst rating found for Regeneron Pharmaceuticals Inc

Company Overview Regeneron Pharmaceuticals Inc

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroi...Read More

https://www.regeneron.com

777 Old Saw Mill River Road, Tarrytown, NY, United States, 10591-6707

13,677

December

USD

USA

Adjusted Closing Price for Regeneron Pharmaceuticals Inc (REGN)

Loading...

Unadjusted Closing Price for Regeneron Pharmaceuticals Inc (REGN)

Loading...

Share Trading Volume for Regeneron Pharmaceuticals Inc Shares

Loading...

Compare Performance of Regeneron Pharmaceuticals Inc Shares

Symbol Capital Gain Dividend Return Total Return
Loading...
Loading...

Technical Indicators for REGN

Assets

Top Holdings

Top Sectors

Top Regions

Stocks Similar To Regeneron Pharmaceuticals Inc (Sector: Biotechnology )

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
VRTX
Vertex Pharmaceuticals Inc 0.00 (0.00%) USD122.24B 30.78 20.00

ETFs Containing REGN

Symbol Name REGN's Weight Expense Ratio Price(Change) Market Cap
IBB
iShares Biotechnology ETF 8.73 % 0.45 % 0.00 (0.00%) USD7.43B

Frequently Asked Questions About Regeneron Pharmaceuticals Inc (REGN) Stock

Based on ratings from 11 analysts Regeneron Pharmaceuticals Inc's stock is Buy . Stock Target Advisor's fundamental analysis is Bullish . The stock has 11 buy, 2 sell and 4 hold ratings.

Unfortunately we do not have enough data on REGN's stock to indicate if its a good dividend stock.

Based on targets from 11 analysts, the average taret price for REGN is USD 1,017.13 over the next 12 months. The maximum analyst target price is USD 1229 while the minimum anlayst target price is USD 710.

REGN stock's Price/Earning ratio is 30.84. Our analysis grades REGN stock's Price / Earning ratio at F. This means that REGN stock's Price/Earning ratio is above 81% of the stocks in the Biotechnology sector in the NSD exchange. Based on this REGN may be a overvalued for its sector.

The last closing price of REGN's stock was USD 1,039.11.

The most recent market capitalization for REGN is USD 115.08B.

Based on targets from 11 analysts, the average taret price for REGN is projected at USD 1,017.13 over the next 12 months. This means that REGN's stock price may go down by -2.12% over the next 12 months.

Following are ETFs with the highest allocation to Regeneron Pharmaceuticals Inc's stock :

IBB

As per our most recent records Regeneron Pharmaceuticals Inc has 13,677 Employees.

Regeneron Pharmaceuticals Inc's registered address is 777 Old Saw Mill River Road, Tarrytown, NY, United States, 10591-6707. You can get more information about it from Regeneron Pharmaceuticals Inc's website at https://www.regeneron.com.
Heading 1 Heading 2 Heading 3 Heading 4 Heading 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5

Stock Target Advisor's Analysis

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

Icon
What to like

Icon
What not to like

Loading...